BAKER BROS. ADVISORS LP
CIK 1263508 · last filed 2026-07-02
BAKER BROS. ADVISORS LP is a corporate insider who has filed 94 SEC Form 4 insider transactions across 25 companies since 2012. The most recent filing, for KOD, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$3.38B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.88B across reported positions. The firm reports its address in New York, NY. 591 SEC filings were submitted jointly with JULIAN BAKER.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.88B
Companies
25
Total Filings
94
Lifetime Open-Market Net
$3.38B
Filer Profile
Reported Address
860 WASHINGTON STREET3RD FLOOR
NEW YORK, NY 10014
Phone
(212) 339-5600
State of Incorporation
DE
Formerly Known As
BAKER BROS ADVISORS LLC (2003–2013)
Related Filers
JULIAN BAKER — 591 joint filings, latest 2026-08-11
FELIX BAKER — 585 joint filings, latest 2026-08-11
Baker Bros. Advisors (GP) LLC — 555 joint filings, latest 2026-08-11
Baker Brothers Life Sciences LP — 525 joint filings, latest 2026-08-11
667, L.P. — 520 joint filings, latest 2026-08-11
14159, L.P. — 215 joint filings, latest 2019-10-03
INCYTE CORP — 96 joint filings, latest 2026-07-02
Baker Bros. Investments, L.P. — 81 joint filings, latest 2019-10-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KOD | Director | 15,316,021 | $32.89 | $503.74M | $106.09M | 5 | 2026-07-02 |
| PRLD | Director | — | $4.59 | — | $0 | 2 | 2026-04-22 |
| BCYC | Director | 937,483 | $3.86 | $3.62M | $0 | 1 | 2026-01-06 |
| KALA | 930 | $0.57 | $532 | -$4.23M | 1 | 2025-10-02 | |
| KYMR | Director | 534,134 | $114.96 | $61.40M | $173.05M | 2 | 2025-06-30 |
| ACAD | Director | 39,468,841 | $27.83 | $1.10B | $1.96B | 10 | 2025-06-02 |
| INCY | Director | 314,600 | $121.47 | $38.21M | $1.09B | 11 | 2025-04-02 |
| IMCR | Director | 2,144,060 | $32.60 | $69.90M | $143.96M | 2 | 2025-03-19 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 136,517 | $184.71 | $25.22M | -$1.48B | 8 | 2024-12-10 |
| MDGL | Director | 179,279 | $534.49 | $95.82M | $135.10M | 3 | 2024-03-25 |
| Atreca, Inc. (BCEL) Delisted | 2,971,128 | $0.15 | $445.7K | -$442.3K | 1 | 2023-10-23 | |
| TCRX | Director | — | $0.32 | — | $0 | 1 | 2023-06-15 |
| Seagen Inc. (SGEN) Delisted | Director | 42,989,787 | $228.74 | $9.83B | $955.17M | 9 | 2022-05-17 |
| KNSA | Director | — | $76.27 | — | $0 | 2 | 2020-07-02 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 1 | 2019-10-15 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 2,883,204 | $1.27 | $3.66M | $301.82M | 1 | 2019-09-20 |
| Aceragen, Inc. (IDRA) Delisted | Director | 253,701 | $7.22 | $1.83M | $45.50M | 4 | 2019-07-03 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 7,641,248 | — | — | -$413.77M | 10 | 2019-06-18 |
| HOOKIPA Pharma Inc. (HOOK) Delisted | 82,073 | $1.15 | $94.4K | $50.00M | 1 | 2019-04-23 | |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 2,372,355 | $58.70 | $139.26M | $28.00M | 2 | 2017-11-13 |
| Neurogene Inc. (AQXP) Delisted | Director | 9,412,424 | — | — | $170.50M | 4 | 2017-05-09 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | 10%+ Owner | 43,476 | $0.07 | $3.3K | $8.00M | 1 | 2017-03-28 |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | 734,261 | $0.09 | $65.4K | $17.60M | 1 | 2016-11-18 |
| BCRX | 10%+ Owner | 1,680,147 | $8.12 | $13.64M | -$65.62M | 3 | 2016-08-16 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 0 | — | — | $158.62M | 2 | 2015-06-23 |
Recent Filings
94 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | KOD | Grant (A) | — | $0 | EDGAR |
| 2026-04-22 | PRLD | Buy (P) | — | $0 | EDGAR |
| 2026-01-06 | BCYC | Grant (A) | +228,000 | $0 | EDGAR |
| 2025-10-02 | KALA | Sell (S) | −2,921,632 | -$4.23M | EDGAR |
| 2025-08-18 | — | U | −24,722,460 | $0 | |
| 2025-06-30 | KYMR | Buy (P) | +3,933,000 | $173.05M | EDGAR |
| 2025-06-02 | ACAD | Grant (A) | +194,568 | $0 | EDGAR |
| 2025-04-02 | INCY | Grant (A) | +5,844 | $0 | EDGAR |
| 2025-03-19 | IMCR | Mixed | +4,844,028 | $143.96M | EDGAR |
| 2024-12-10 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −6,222,102 | -$1.17B | EDGAR |
Showing 1–10 of 94
Page 1 of 10
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.